Camrelizumab (Camre) plus taxane-based chemotherapy (CT): Clinical outcomes and dynamic monitoring of CEA as a predictive biomarker of response in patients with recurrent or advanced esophageal squamous cell carcinoma (ESCC).

被引：0
|
作者：
Kong, Cheng
Xu, Jianhua
Jiang, Ming
Zhu, Xiangzhi
Ye, Jinjun
Yu, Shaorong
Zhu, Jun
机构：
[1] Jiangsu Canc Hosp, Nanjing, Peoples R China
[2] Nanjing Med Univ, Jiangsu Canc Hosp, Dept Radiat Oncol, Nanjing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16524
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Can 18F-FDG PET/CT Radiomics Features Predict Clinical Outcomes in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma?
    Jayaprakasam, Vetri Sudar
    Gibbs, Peter
    Gangai, Natalie
    Bajwa, Raazi
    Sosa, Ramon E.
    Yeh, Randy
    Greally, Megan
    Ku, Geoffrey Y.
    Gollub, Marc J.
    Paroder, Viktoriya
    CANCERS, 2022, 14 (12)
  • [32] A single-arm, exploratory study of disitamab vedotin (DV) combined with camrelizumab and platinum-based chemotherapy as first-line treatment in patients with HER2 expressing locally advanced or metastatic esophageal squamous cell carcinoma (ESCC).
    Wu, Meihong
    Zhang, Yingyi
    Feng, Dan
    Wang, Bin
    Wang, Wei
    Chen, Tianran
    Zhao, Anjing
    Xu, Meng
    Zhang, Linli
    Zhan, Xianbao
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : TPS217 - TPS217
  • [33] Clinical Efficacy of Taxol Plus Platinum (TP) Chemotherapy Combined with Delayed Administration of PD-1 Inhibitors in Patients with Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma: A Retrospective Study
    Shen, Lin
    Chen, Zixuan
    Zhang, Zhi
    Wu, Yunjiang
    Ren, Yue
    Li, Ying
    Li, Yue
    Yin, Xudong
    Han, Fang
    Chen, Yong
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2024, 18 : 2761 - 2773
  • [34] A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy
    Shirakawa, Tsuyoshi
    Kato, Ken
    Nagashima, Kengo
    Nishikawa, Akiko
    Sawada, Ryoichi
    Takahashi, Naoki
    Shoji, Hirokazu
    Sasaki, Yusuke
    Honma, Yoshitaka
    Iwasa, Satoru
    Takashima, Atsuo
    Okita, Natsuko
    Hamaguchi, Tetsuya
    Yamada, Yasuhide
    Shimada, Yasuhiro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (06) : 1207 - 1215
  • [35] A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy
    Tsuyoshi Shirakawa
    Ken Kato
    Kengo Nagashima
    Akiko Nishikawa
    Ryoichi Sawada
    Naoki Takahashi
    Hirokazu Shoji
    Yusuke Sasaki
    Yoshitaka Honma
    Satoru Iwasa
    Atsuo Takashima
    Natsuko Okita
    Tetsuya Hamaguchi
    Yasuhide Yamada
    Yasuhiro Shimada
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 1207 - 1215
  • [36] A single-arm phase II study of cabozantinib and atezolizumab in patients with recurrent or metastatic esophageal squamous cell carcinoma (R/M ESCC) who failed platinum-based chemotherapy
    Kuo, Hung-Yang
    Guo, Jhe-Cyuan
    Huang, Ta-Chen
    Lin, Chia-Chi
    Lee, Jang-Ming
    Yeh, Kun-Huei
    Hsu, Chih-Hung
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [37] [18F]AlF-NOTA-FAPI-04 PET/CT for Predicting Pathologic Response of Resectable Esophageal Squamous Cell Carcinoma to Neoadjuvant Camrelizumab and Chemotherapy: A Phase II Clinical Trial
    Dong, Yinjun
    Wang, Zhendan
    Hu, Xinying
    Sun, Yuhong
    Qin, Jingjie
    Qin, Qiming
    Liu, Shuguang
    Yuan, Shuanghu
    Yu, Jinming
    Wei, Yuchun
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (11) : 1702 - 1709
  • [38] First-line (1L) tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 Japanese subgroup analysis with longer follow-up.
    Kojima, Takashi
    Ogata, Takashi
    Ishihara, Ryu
    Hara, Hiroki
    Sun, Tianmo
    Xu, Sheng
    Kato, Ken
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 420 - 420
  • [39] A Quality-adjusted Time Without Symptoms and Toxicity (Q-TWiST) analysis comparing nivolumab plus chemotherapy (N plus CT) or nivolumab plus ipilimumab (N plus I) vs CT in patients (pts) with tumor cell PD-L1 ≥ 1% advanced esophageal squamous cell carcinoma (ESCC): CheckMate 648
    Chau, I.
    Bridgewater, J. A.
    Wyrwicz, L. S.
    Greenwood, M.
    Blum, S. I.
    Moreno-Koehler, A.
    Martin, E.
    Taylor, F.
    Davis, C.
    Singh, P.
    ANNALS OF ONCOLOGY, 2024, 35 : S162 - S162
  • [40] Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody
    Wang, Xi
    Zhang, Bo
    Chen, Xuelian
    Mo, Hongnan
    Wu, Dawei
    Lan, Bo
    Li, Qun
    Xu, Binghe
    Huang, Jing
    THORACIC CANCER, 2019, 10 (06) : 1395 - 1401
12345